Next 10 |
home / stock / sonn / sonn articles
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining more than 300 points on Thursday. The Dow traded up 0.87% to 3...
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 20...
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 50 points on Thursday. Following the market opening Thursd...
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 8.5% to $1.18 Thursday morning on downward momentum. The...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% t...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 150 points on Wednesday. The Dow traded up 0.20...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company ...
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
Sonnet BioTherapeutics Holdings Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 3.5% to $130.78 on volume of 504,910,586 shares Nikola Corporation (NKLA) fell 31.5% to $0.3296 on volume of 265,124,783 shares SMX (Security Matters) Public Limited Company (SMX) rose 35.1% to $0.1608 o...
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the entry into a definitive agreement for the immed...
Sonnet discovered and characterized a modified version of Interleukin-18 (IL-18 Binding Protein Resistant or IL-18 BPR ) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 Binding Protein (IL-18BP) ...